Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: biosimilar

Reap the Rewards of State Society Involvement

  |  

Getting involved with your state society offers many benefits, from personal pride and group engagement, to “promoting good ideas, as well as stopping bad ideas from becoming laws that can harm your patients,” says Robert Levin, MD, immediate past president of the Florida Society of Rheumatology (FSR). That’s why he has been involved in leadership…

RISE Lifts Research: The 2018 Annual Meeting Features 6 New Studies Based on RISE Data

  |  

Data from the ACR’s Rheumatology Informatics System for Effectiveness (RISE) were used by rheumatology researchers in a crop of new studies that will be presented at the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Six abstracts, including four oral and two poster presentations, were accepted for this year’s meeting. They explore topics ranging from…

EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray

  |  

In late July, the European Commission granted marketing approval for Hyrimoz, which is biosimilar to adalimumab…

4 Rheumatoid Arthritis Therapy Principles, & New Drug Info

  |  

CHICAGO—Amid what she called a “dizzying array of choices” for rheumatoid arthritis (RA)—from anti-TNF and anti-IL6-receptor therapies to B cell depletion to new biosimilar options—disease treatment should still revolve around several basic concepts, an expert said at the ACR State-of-the-Art Clinical Symposium in April. Joan Bathon, MD, chief of rheumatology at Columbia University in New…

RheumPAC Members Speak Out on the Importance of Political Action Committees

  |  

People can support causes, committees, campaigns, etc. in infinite ways. Members of the ACR/ARHP can see their efforts magnified via an investment in the ACR’s political action committee, RheumPAC. Your contribution goes directly to help support rheumatology and rheumatologists around the country. Proof of any group’s success can be seen in the satisfaction of its…

ACR & NPF Highlight Medicare Access Challenges in Capitol Hill Briefing

  |  

Concerns about how the Trump administration’s ideas to lower drug prices could reduce patient access to medicines led the ACR to speak out on many different fronts. On June 25, at a briefing hosted by the ACR and the National Psoriasis Foundation (NPF), a packed room of Congressional staffers and reporters learned from rheumatologists and…

ACR Responds to Drug Pricing Proposals

  |  

Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…

AMA House of Delegates 2018 Annual Meeting Recap

Gary Bryant, MD  |  

On June 8–13, the AMA House of Delegates (HOD) came together in Chicago for its 2018 Annual Meeting. With the recent change in apportionment of geographic and specialty delegates now equal to each other, more than 600 members of the HOD were present, with several hundred staff and attendees from the AMA and other medical…

The ACR’s Congressional Advocacy Produces Results

David I. Daikh, MD, PhD  |  

The underlying tenet of the ACR’s advocacy efforts is that we cannot effect change for our profession and our patients unless we take our issues directly to decision makers. As I write this column, I am highly encouraged by the progress we have made so far this year in the advocacy realm. At the same…